CTIS2023-509504-15-00招募中1 期
C4391002 - A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS - C4391002
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Pfizer Inc.
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male and female participants = 18 years of age at Visit 1., Histological or cytological diagnosis of locally advanced or metastatic solid tumor/diagnosis which is unresectable., Evaluable lesion (including skin or bone lesion only, Part 1)., Participants entering the study in the expansion cohort have at least 1 measurable lesion as defined by RECIST (version 1.1) that has not been previously irradiated., Cancer type: • HR-positive HER2negative tumor (Part 1 and Part 2) • HR-positive HER2-positive tumor (Part 1) • Advanced solid tumor or metastatic disease (Part 1) • ECOG PS 0 or 1.
排除标准
- •Prior/concomitant treatment as follows: • prior treatment with any CDK 4/6 inhibitor, or fulvestrant, or everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway (Part 2B); • prior neoadjuvant or adjuvant treatment with a non-steroidal AI (ie, anastrozole or letrozole) with disease recurrence while on or within 12 months of completing treatment (Part 2C); • prior treatment with any CDK4/6 inhibitor for advanced disease (Part 2B and 2C); • radiation therapy within 4 weeks prior to study enrollment, with the exception of palliative radiotherapy following discussion with the sponsor., Inadequate organ function., Known bleeding disorders., Participation in other studies involving investigational drug(s) within 4 weeks (or 5 half--lives, whichever is shorter) prior to study entry., Participants with any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix, Bowen’s disease., Current use or anticipated need for PPI within 7 days prior to first dose of the study intervention. For participants with gastroesophageal reflux disease, concurrent treatment with PPIs is not allowed and treatment with H2 blockers and/or antacids if medically required must be dosed according to protocol guidelines., Previous high-dose chemotherapy requiring stem cell rescue., Last anticancer treatment within 2 weeks (or 5 half-lives, whichever is shorter, unless the last immediate anticancer treatment contained an antibody-based agent(s) (approved or investigational), then the interval of 4 weeks or 5 half-lives (whichever is shorter) is required prior to receiving the study intervention (except in Part 2C where no systemic anticancer treatment in advanced or metastatic setting is allowed).
研究者
相似试验
招募中
1 期
ZN-c3 in Adult Participants With Metastatic Colorectal Cancermetastatic colorectal cancerMedDRA version: 21.0Level: LLTClassification code: 10052362Term: Metastatic colorectal cancer Class: 10029104CTIS2022-502267-37-00K-Group Beta Inc.82
招募中
1 期
INCB 39110-801 A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (INCB039110)postlung transplant (BOS)chronic graft-versus-host diseaseMedDRA version: 23.0Level: LLTClassification code: 10083303Term: Bronchiolitis obliterans syndrome Class: 10038738MedDRA version: 20.0Level: PTClassification code: 10028537Term: Myelofibrosis Class: 100000004864MedDRA version: 20.1Level: PTClassification code: 10066261Term: Chronic graft versus host disease Class: 100000004870MyelofibrosisCTIS2022-501661-47-00Incyte Corp.14
进行中（未招募）
不适用
A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 or 24 Months of Age in Subjects Who Previously Received a Three-Dose Primary Series of the Novartis Meningococcal B Recombinant Vaccine as Infants in Study V72P12 - NDProphylaxis against Meningitis and/or Septicemia due to Meningococcus B.MedDRA version: 12.0Level: LLTClassification code 10027249Term: Meningitis meningococcalEUCTR2009-011676-30-ITOVARTIS VACCINES AND DIAGNOSTICS S.R.L.1,900
进行中（未招募）
1 期
A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 or 24 Months of Age in Subjects Who Previously Received a Three-Dose Primary Series of the Novartis Meningococcal B Recombinant Vaccine as Infants in Study V72P12EUCTR2009-011676-30-BEovartis Vaccines and Diagnostics S.r.l.1,900
进行中（未招募）
1 期
A Phase 2b, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis Meningococcal B Recombinant Vaccine Administered at 12, 18 or 24 Months of Age in Subjects Who Previously Received a Three-Dose Primary Series of the Novartis Meningococcal B Recombinant Vaccine as Infants in Study V72P12EUCTR2009-011676-30-GBovartis Vaccines and Diagnostics S.r.l.1,588